A breakthrough innovation from the University of Saskatchewan could potentially reduce the duration of calving season, the most labor-intensive period for beef producers. The discovery involves the adaptation of Cetrorelix, a hormone drug commonly utilized in human in vitro fertilization (IVF), for cattle reproduction and beyond, showing promising results in research conducted at the university in Saskatoon.
Dr. Jaswant Singh, a veterinary medicine expert and researcher at the Western College of Veterinary Medicine, stumbled upon the potentials of Cetrorelix during an unrelated study eight years ago. He acknowledges the contributions of graduate students Dylan Farmer and Carlos Leonardi to this innovative development.
Describing the findings from a trial involving 200 cows, Singh expressed enthusiasm for the drug’s efficacy, stating that it represents a significant advancement in reproductive technologies for cattle. While still in the early stages of development, Cetrorelix has shown remarkable potential as an ovulation synchronization method, facilitating simultaneous pregnancies through IVF and potentially leading to synchronized calving.
Although several synchronization methods exist, Cetrorelix stands out as a potentially superior option that could streamline the calving period, leading to cost savings on labor and improved animal management practices. Singh highlighted the economic benefits, emphasizing that early calving could result in higher weaning weights, translating to increased profitability for farmers.
Garner Deobald, a beef rancher and marketing manager at BoviGen Genetic Services, expressed keen interest in adopting Cetrorelix if proven effective. He emphasized the importance of incorporating innovative tools like Cetrorelix to enhance breeding practices and maximize outcomes for both his own cattle and clients at BoviGen.
Aside from its reproductive benefits, Cetrorelix could also promote the adoption of artificial insemination as a preferred breeding technique, offering opportunities for improved genetic selection within herds and more accurate calf performance predictions.
Dr. Singh revealed that the university has filed for a patent on the drug and is collaborating with pharmaceutical companies to bring it to market. He expressed optimism about the global potential of Cetrorelix, foreseeing increased utilization of artificial insemination in cattle breeding practices worldwide.
Tag: rewrite-done
